Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia

Annals of Pharmacotherapy

Volumn 38, Issue 1, 2004, Pages 134-141

  Liu, Gordon G ^a   Sun, Shawn X ^a   Christensen, Dale B ^a   Luo, Xuemei ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Cost; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; OLANZAPINE; RISPERIDONE;

ADULT; COMPARATIVE STUDY; COST CONTROL; COST OF ILLNESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; ECONOMICS; EMERGENCY HEALTH SERVICE; FEE; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 0346362455     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C485     Document Type: Review

References (63)

1. Keith SJ, Regier DA, Rae DS. Schizophrenia disorders. In: Robins LN, Regier DA. eds. Psychiatric disorder in America: the Epidemiological Catchment Area Study. New York: The Free Press, 1991:11-32.
2. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94.
3. Rice DP. Economic burden of mental disorders in the United States. Econ Neurosci 1999;1:40-4.
4. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States. 1989-1997. Psychiatr Serv 2002;53:425-30.
5. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
6. Sacristan JA, Gomez JC, Montejo AL, Vieta E, Gregor KJ, EFESO Study Group. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin Ther 2000;22:583-99.
7. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR. et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-58.
8. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
9. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-63.
10. Kasper S, Rosillon D, Duchesne I. Risperidone-Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:179-87.
11. Prosyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with inhospital treatment with risperidone or olanzapine. Clin Ther 1998;20:1203-17.
12. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
13. Dinakar HS, Sobel RN, Bopp JH, Daniels A, Mauro S. Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among Long-Stay State Hospital patients. Psychiatr Serv 2002;53:755-7.
14. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9.
15. Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002;53:891-3.
16. Del Paggio D. Economic issues associated with antipsychotic agents. Direct Psychiatry 2000;20:43-8.
17. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567-79.
18. Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment schizophrenia. Managed Care Interface 2002;15:75-81.
19. Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia. Pharmacoeconomics 2003;21:683-97.
20. Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001;62:749-56.
21. Fuller MA, Shermock KM, Secic M, Laich JS, Durkin MB. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv 2002;53:855-60.
22. Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003;54:742-4.
23. Fichtner CG, Hanrahan P, Luchins DJ. Pharmacoeconomic studies of atypical antipsychotics: review and perspective. Psychiatr Ann 1998;28:381-96.
24. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998;14:97-133.
25. Foster RH, Goa KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999;15:611-40.
26. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Pharmacoeconomics 2000;18:105-24.
27. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000;34:200-7. DOI 10.1345/aph.18458
28. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-61.
29. Karki SD. Cost-effectiveness of atypical antipsychotic drugs for schizophrenia. Drug Benefit Trends 2001;13(suppl D):1-13.
30. Shaw JW. Economic evaluations of olanzapine and risperidone. Am J Health Syst Pharm 2002;59:1366-75.
31. Aronson SM. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997;19:139-47.
32. Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. Psychiatr Serv 1999;50:163-4, 168.
33. Thompson D. Cost of switching from neuroleptics to risperidone and clozapine: pilot study of the San Diego County Mental Health Services. Clin Drug Invest 1997;14:428-33.
34. Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacol Bull 1998;34:373-82.
35. Gianfrancesco F, Durkin MB, Mahmoud R, Wang R. Use of health care services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics 2002;20:413-27.
36. Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 1999;60:850-6.
37. Hammond CM, Pierson JF, Grande TP, Munetz MR, Wilson DA, Pathak DS. Economic evaluation of risperidone in an outpatient population. Ann Pharmacother 1999;33:1160-6.
38. Carter C, Stevens M, Durkin M. Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. Clin Ther 1998;20:352-63.
39. Nightengale BS, Garrett L, Waugh S, Lawrence BJ, Andrus J. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. Am J Managed Care 1998;4:360-6.
40. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv 1999;50:228-32.
41. Shermock KM, Sadik MK, Kozma CM, Sesti AM, Reeder CE. Risperidone, haloperidol and clozapine in the South Carolina Medicaid program: a comparative analysis of utilization and expenditure. Dis Manage Health Outcomes 2001;9:203-13.
42. Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997;48:1153-9.
43. Guest JF, Hart WM, Cookson R, Lindstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996;10:59-67.
44. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, Lorier JL. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Pharmacoecon 1996;11:289-98.
45. Keegan DL, Albright P, Peterson T. Long-term healthcare resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia. Clin Drug Invest 1999;18:233-7.
46. Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998;34:75-81.
47. Rimel M, Cates M. Cost-savings associated with risperidone therapy in a Veterans Affairs Medical Center. P & T 2000;25:244-7.
48. Hamilton SH, Revicki DA, Edgett ET, Genduso LA, Tollefson GI. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 1999;15:469-80.
49. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999;60(suppl 19):38-45.
50. Sacristan JA, Gomez JC, Martin J, Garcia-Bernardo E, Peralta V, Alvarrez E, et al. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. Clin Drug Invest 1998;15:29-35.
51. Del Paggio D, Finley PR, Cavano JM. Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population. Clin Ther 2002;24:803-17.
52. Tollefson GD, Beasley CM, Tran PV, Sweet JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
53. Malla AK, Norman RM, Scholten DJ, Zirul S, Kotteda V. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001;62:179-84.
54. Sauriol L, Laporta M, Edwardes MD, Deslandes M, Richard N, Suissa S. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther 2001;23: 942-56.
55. Rabinowiz J, Lichtenberg P, Kaplan Z. Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 2000;46:91-6.
56. Kasper S, Jones M, Duchesne I. Risperidone-Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:189-96.
57. Kelly DL, Nelson NW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv 2001;52:676-8.
58. International classification of diseases. 9th rev. Clinical modification. Washington, DC: Department of Health and Human Services.
59. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
60. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
61. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201.
62. Green B. Focus on risperidone. Curr Med Res Opin 2000;16:57-65.
63. Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol 2001;21:448-53.